/ Cadila's Subsidiary Settles Its Patent Litigation ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Friday, 13 January 2017


Zydus Pharmaceuticals (USA) Inc., a subsidiary of Cadila Healthcare Limited, which is a global pharmaceuticals company, has today announced that they have finalised an agreement with Upsher-Smith Laboratories Inc., to settle the patent litigation with reference to Qudexy capsules.

Headquartered at Ahmedabad, Gujarat, Cadila Healthcare is an Indian pharmaceutical company with a revenue of Rs 54.7 billion. It is the fourth largest pharmaceutical company in India. Cadila Healthcare is currently trading at Rs 350.70 per share and is up by 0.30%. The stock has delivered 9.59% returns over a period of one year. Over a three year period the stock has delivered 26.03% on an annualised basis, and over a five year period the stock has delivered 20.79% returns on an annualised basis.

The stock has underperformed the BSE Sensex and has outperformed the BSE Healthcare index over a period of one year.

The scrip opened at Rs 352 and has touched a high and low of Rs 356.4 and Rs 346.1 respectively. So far 823738(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 35877.06 crore.

The BSE group 'A' stock of face value Rs 1 has touched a 52 week high of Rs 429.45 on 01-Nov-2016 and a 52 week low of Rs 295.5 on 18-Jan-2016. Last one week high and low of the scrip stood at Rs 384.85 and Rs 346.3 respectively. The promoters holding in the company stood at 74.79 % while Institutions and Non-Institutions held 17.18 % and 8.03 % respectively. The stock is currently trading below its 100 DMA.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717

0 comments: